

APPLICATION NO.

FILING DATE

UNITED STATES DE ARTMENT OF COMMERCE Patent and Trad mark Office

Address: COMMISSIONER OF PATENTS AND TRADEMARKS

Washington, D.C. 20231

FIRST NAMED INVENTOR ATTORNEY DOCKET NO.

EXAMINER

ART UNIT PAPER NUMBER

DATE MAILED:

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trademarks

Office Action Summary

Application No. 09/202,681

Richard Hutson

Applica (s)

Examiner

Group Art Unit

Mathur et al.

1652



X Responsive to communication(s) filed on _	Sep 18, 2000
This action is FINAL.	
Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under Ex parte QuayNe35 C.D. 11; 453 O.G. 213	
longer, from the mailing date of this communi	his action is set to expire1 month(s), or thirty days, whichever is cation. Failure to respond within the period for response will cause the E. § 133). Extensions of time may be obtained under the provisions of
Disposition of Claim	
X Claim(s) <u>1-12</u>	is/are pending in the applicat
Of the above, claim(s)	is/are withdrawn from consideration
	is/are allowed.
	is/are rejected.
	is/are objected to
	are subject to restriction or election requiremen
Application Papers	
☐ See the attached Notice of Draftsperso	n's Patent Drawing Review, PTO-948.
The drawing(s) filed on	is/are objected to by the Examiner.
☐ The proposed drawing correction, filed	on is is approveddisapproved.
The specification is objected to by the E	Examiner.
The oath or declaration is objected to b	y the Examiner.
Priority under 35 U.S.C. § 119 Acknowledgement is made of a claim 1	for foreign priority under 35 U.S.C. § 119(a)-(d).
-	RTIFIED copies of the priority documents have been
received.	
received in Application No. (Seri	es Code/Serial Number)
received in this national stage a	oplication from the International Bureau (PCT Rule 17.2(a))
*Certified copies not received:	
Acknowledgement is made of a claim	for domestic priority under 35 U.S.C. § 119(e).
Attachment(s)	
Notice of References Cited, PTO-892	
Information Disclosure Statement(s), P	TO-1449, Paper No(s)
∑ Interview Summary, PTO-413	Product PTO 040
Notice of Draftsperson's Patent Drawin	
Notice of Informal Patent Application, F	21O-102
SEE 0	DFFICE ACTION ON THE FOLLOWING PAGES

Application/Control Number: 09202681

Art Unit: 1652

DETAILED ACTION

1. The art unit location of your application and examiner has changed. To aid in correlating any papers for this application, all further correspondence regarding this application should be directed to Group Art Unit 1652, Examiner Richard Hutson Ph.D.

Election/Restrictions

2. This application contains claims directed to more than one species of the generic invention. These species are deemed to lack unity of invention because they are not so linked as to form a single general inventive concept under PCT Rule 13.1.

The species are as follows:

Each of the polynucleotides selected from the group consisting of SEQ ID NO: 19-27, 37-41, 43, 45, 47, 49, 51, and 53 are considered different species. Included with each of these species are also the proteins encoded by each polynucleotide.

Applicant is required, in reply to this action, to elect a single species to which the claims shall be restricted if no generic claim is finally held to be allowable. The reply must also identify the claims readable on the elected species, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered non-responsive unless accompanied by an election.

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37 CFR 1.141. If claims are added after

Page 3

Application/Control Number: 09202681

Art Unit: 1652

the election, applicant must indicate which are readable upon the elected species. MPEP § 809.02(a).

3. The claims are deemed to correspond to the species listed above in the following manner:
All claims are generic.

The species listed above do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, the species lack the same or corresponding special technical features for the following reasons: Each of designated species are drawn to a independent polynucleotide, vector and host cell comprising said polynucleotide, protein encoded by said polynucleotide and methods of using said polynucleotide or protein.

- 4. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a petition under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).
- 5. It is acknowledged that the previous office action was on the merits of all of the above designated species however the application has been transferred to a new examiner and it is believed that a complete examination of the invention requires additional search for each species thus constituting an undue burden of search.

Page 4

Application/Control Number: 09202681

Art Unit: 1652

6. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Richard Hutson whose telephone number is (703) 308-0066. The examiner can normally be reached on M-F from 7:30 to 4:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ponnathapy Achutamurthy (Murthy), can be reached on (703) 308-3804. The fax number for Official Papers to Technology Center 1600 is (703) 305-3014.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-0196.

Richard Hutson Ph.D. 11/28/2000

Leven Burty